Potential Synergistic Protection of Retinal Ganglion Cells from Axotomy-Induced Apoptosis by Adenoviral Administration of Glial Cell Line-Derived Neurotrophic Factor and X-Chromosome-Linked Inhibitor of Apoptosis

2002 ◽  
Vol 11 (1) ◽  
pp. 123-133 ◽  
Author(s):  
Guido Straten ◽  
Christian Schmeer ◽  
Alexandra Kretz ◽  
Ellen Gerhardt ◽  
Sebastian Kügler ◽  
...  
2009 ◽  
Vol 89 (6) ◽  
pp. 1012-1020 ◽  
Author(s):  
Maria Voss Kyhn ◽  
Henry Klassen ◽  
Ulrica Englund Johansson ◽  
Karin Warfvinge ◽  
Erin Lavik ◽  
...  

2002 ◽  
Vol 15 (4) ◽  
pp. 637-643 ◽  
Author(s):  
Christian Schmeer ◽  
Guido Straten ◽  
Sebastian Kügler ◽  
Claude Gravel ◽  
Mathias Bähr ◽  
...  

Cells ◽  
2020 ◽  
Vol 9 (9) ◽  
pp. 2082 ◽  
Author(s):  
Simon Dulz ◽  
Mahmoud Bassal ◽  
Kai Flachsbarth ◽  
Kristoffer Riecken ◽  
Boris Fehse ◽  
...  

We have recently demonstrated that neural stem cell-based intravitreal co-administration of glial cell line-derived neurotrophic factor (GDNF) and ciliary neurotrophic factor (CNTF) confers profound protection to injured retinal ganglion cells (RGCs) in a mouse optic nerve crush model, resulting in the survival of ~38% RGCs two months after the nerve lesion. Here, we analyzed whether this neuroprotective effect is long-lasting and studied the impact of the pronounced RGC rescue on axonal regeneration. To this aim, we co-injected a GDNF- and a CNTF-overexpressing neural stem cell line into the vitreous cavity of adult mice one day after an optic nerve crush and determined the number of surviving RGCs 4, 6 and 8 months after the lesion. Remarkably, we found no significant decrease in the number of surviving RGCs between the successive analysis time points, indicating that the combined administration of GDNF and CNTF conferred lifelong protection to injured RGCs. While the simultaneous administration of GDNF and CNTF stimulated pronounced intraretinal axon growth when compared to retinas treated with either factor alone, numbers of regenerating axons in the distal optic nerve stumps were similar in animals co-treated with both factors and animals treated with CNTF only.


2021 ◽  
Vol 14 (1) ◽  
pp. 50
Author(s):  
Alicia Arranz-Romera ◽  
Maria Hernandez ◽  
Patricia Checa-Casalengua ◽  
Alfredo Garcia-Layana ◽  
Irene T. Molina-Martinez ◽  
...  

We assessed the sustained delivery effect of poly (lactic-co-glycolic) acid (PLGA)/vitamin E (VitE) microspheres (MSs) loaded with glial cell-derived neurotrophic factor (GDNF) alone (GDNF-MSs) or combined with brain-derived neurotrophic factor (BDNF; GDNF/BDNF-MSs) on migration of the human adult retinal pigment epithelial cell-line-19 (ARPE-19) cells, primate choroidal endothelial (RF/6A) cells, and the survival of isolated mouse retinal ganglion cells (RGCs). The morphology of the MSs, particle size, and encapsulation efficiencies of the active substances were evaluated. In vitro release, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell viability, terminal deoxynucleotidyl transferase (TdT) deoxyuridine dUTP nick-end labelling (TUNEL) apoptosis, functional wound healing migration (ARPE-19; migration), and (RF/6A; angiogenesis) assays were conducted. The safety of MS intravitreal injection was assessed using hematoxylin and eosin, neuronal nuclei (NeuN) immunolabeling, and TUNEL assays, and RGC in vitro survival was analyzed. MSs delivered GDNF and co-delivered GDNF/BDNF in a sustained manner over 77 days. The BDNF/GDNF combination increased RPE cell migration, whereas no effect was observed on RF/6A. MSs did not alter cell viability, apoptosis was absent in vitro, and RGCs survived in vitro for seven weeks. In mice, retinal toxicity and apoptosis was absent in histologic sections. This delivery strategy could be useful as a potential co-therapy in retinal degenerations and glaucoma, in line with future personalized long-term intravitreal treatment as different amounts (doses) of microparticles can be administered according to patients’ needs.


Sign in / Sign up

Export Citation Format

Share Document